Your browser doesn't support javascript.
loading
Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines
Atıcı, Serkan; Soysal, Ahmet; Gönüllü, Erdem; Aydemir, Gökhan; Öner, Naci; Alan, Servet; Engin, Havva; Yıldız, Melek; Karaböcüoğlu, Metin.
  • Atıcı, Serkan; Okan University School of Medicine. Division of Pediatric Infectious Diseases. İstanbul. TR
  • Soysal, Ahmet; Memorial Ataşehir Hospital. Division of Pediatric Infectious Diseases. İstanbul. TR
  • Gönüllü, Erdem; Istanbul Health and Technology University. Department of Pediatrics. İstanbul. TR
  • Aydemir, Gökhan; Haliç University. Department of Pediatrics. İstanbul. TR
  • Öner, Naci; Istanbul Health and Technology University. Department of Pediatrics. İstanbul. TR
  • Alan, Servet; Memorial Ataşehir Hospital. Clinic of Infectious Diseases. İstanbul. TR
  • Engin, Havva; Memorial Ataşehir Hospital. Clinic of Infectious Diseases. İstanbul. TR
  • Yıldız, Melek; Memorial Şişli Hospital. Clinic of Infectious Diseases. İstanbul. TR
  • Karaböcüoğlu, Metin; Biruni University. Department of Pediatrics. İstanbul. TR
Rev. Soc. Bras. Med. Trop ; 56: e0046, 2023. tab, graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1449353
ABSTRACT
ABSTRACT

Background:

Heterologous COVID-19 booster vaccination is an alternative strategy to homologous vaccination, especially in developing countries, due to shortages, delays, or unequal distribution of COVID-19 vaccines. We compared cohorts vaccinated with different vaccine combinations to investigate whether a heterologous booster dose of mRNA-based BNT162b2 vaccine boosts the immune response in individuals primed with the CoronaVac vaccine.

Methods:

Anti-RBD IgG is generally measured 4 weeks after primary immunization and 4 weeks after booster vaccination. Data on anti-receptor-binding domain (anti-RBD) IgG antibody titers and clinical characteristics were provided by infection control units.

Results:

The highest median anti-RBD IgG antibody titers (14589 AU/mL) after primary immunization was observed in the group vaccinated with two doses of BNT162b2 vaccine. Antibody titers were lower 4 months or more after the second CoronaVac vaccine dose in CoronaVac recipients with or without previous COVID-19. In the homologous COVID-19 booster vaccine group (primed with two doses of CoronaVac 4 weeks apart and a single booster dose of CoronaVac) the median anti-RBD titers decreased from 1025 to 242 AU/mL before the booster dose. In the heterologous group (primed with two doses of CoronaVac 4 weeks apart and a single booster dose of BNT162b2), the median anti-RBD titer increased to 31624 AU/mL, a 132-fold increase, 16 days after the booster dose.

Conclusions:

After the second dose of CoronaVac, protective neutralizing antibody levels decrease over time, and a booster dose is required. Heterologous COVID-19 booster vaccination with BNT162b2 is effective at boosting neutralizing antibody levels.


Texto completo: DisponíveL Índice: LILACS (Américas) Idioma: Inglês Revista: Rev. Soc. Bras. Med. Trop Assunto da revista: Medicina Tropical Ano de publicação: 2023 Tipo de documento: Artigo País de afiliação: Turquia Instituição/País de afiliação: Biruni University/TR / Haliç University/TR / Istanbul Health and Technology University/TR / Memorial Şişli Hospital/TR / Memorial Ataşehir Hospital/TR / Okan University School of Medicine/TR

Similares

MEDLINE

...
LILACS

LIS


Texto completo: DisponíveL Índice: LILACS (Américas) Idioma: Inglês Revista: Rev. Soc. Bras. Med. Trop Assunto da revista: Medicina Tropical Ano de publicação: 2023 Tipo de documento: Artigo País de afiliação: Turquia Instituição/País de afiliação: Biruni University/TR / Haliç University/TR / Istanbul Health and Technology University/TR / Memorial Şişli Hospital/TR / Memorial Ataşehir Hospital/TR / Okan University School of Medicine/TR